|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000263639 |
Summary for MSMB |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000263639 | Gene symbol | MSMB |
| Gene name | microseminoprotein beta | |
| HGNC | 7372 | |
| Entrez ID | 4477 | |
| Gene type | protein_coding | |
| Synonyms | MSMB|PSP-94|PSP57|PSP94|IGBF|MSP|MSPB|PN44|PRPS|PSP | |
| UniProtAcc | P08118 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for MSMB |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| MSMB | 1.38e+03 | 2.59e+00 | 8.75e-01 | 2.95e+00 | 3.13e-03 | 2.55e-02 | BRCA |
| MSMB | 2.32e+02 | 1.11e+00 | 2.55e-01 | 4.36e+00 | 1.28e-05 | 3.08e-04 | HNSC |
| MSMB | 3.64e+00 | 2.78e+00 | 5.53e-01 | 5.02e+00 | 5.14e-07 | 3.06e-05 | SARC |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| MSMB | 8.58e+02 | -1.30e+00 | 5.80e-01 | -2.20e+00 | 2.80e-02 | 4.60e-02 | HNSC |
| MSMB | 1.53e+01 | 1.60e+00 | 4.86e-01 | 3.29e+00 | 1.02e-03 | 2.55e-03 | LIHC |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| MSMB | 4.25e+02 | 2.95e+00 | 2.49e-01 | 1.19e+01 | 2.07e-32 | 1.15e-31 | BRCA |
Top |
Sex-biased somatic mutation for MSMB |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for MSMB |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg23975355 | chr10:46047738 | CGI:chr10:46030173-46030750 | promoter | 8.39e-01 | 5.79e-01 | 3.94e+00 | 8.20e-05 | 1.42e-03 | 2.61e-01 |
| BRCA | cg27607126 | chr10:46046926 | CGI:chr10:46030173-46030750 | promoter | 7.22e-01 | 5.26e-01 | 2.98e+00 | 2.91e-03 | 1.63e-02 | 1.96e-01 |
| BRCA | cg17030820 | chr10:46046561 | CGI:chr10:46030173-46030750 | promoter | 8.71e-01 | 6.96e-01 | 3.28e+00 | 1.04e-03 | 9.62e-03 | 1.75e-01 |
| LUAD | cg10326726 | chr10:46046316 | CGI:chr10:46030173-46030750 | promoter | 5.49e-01 | 4.35e-01 | 4.22e+00 | 2.47e-05 | 1.68e-04 | 1.13e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUAD | cg10326726 | chr10:46046316 | CGI:chr10:46030173-46030750 | promoter | 4.35e-01 | 8.23e-01 | -3.68e+00 | 2.29e-04 | 5.63e-04 | -3.88e-01 |
| LUAD | cg27607126 | chr10:46046926 | CGI:chr10:46030173-46030750 | promoter | 7.25e-01 | 8.41e-01 | -3.78e+00 | 1.55e-04 | 4.06e-04 | -1.16e-01 |
| LUAD | cg17030820 | chr10:46046561 | CGI:chr10:46030173-46030750 | promoter | 6.61e-01 | 8.79e-01 | -4.36e+00 | 1.27e-05 | 5.11e-05 | -2.18e-01 |
| LUAD | cg12083644 | chr10:46046165 | CGI:chr10:46030173-46030750 | promoter,gene body | 7.87e-01 | 9.33e-01 | -3.11e+00 | 1.84e-03 | 3.24e-03 | -1.47e-01 |
| HNSC | cg27607126 | chr10:46046926 | CGI:chr10:46030173-46030750 | promoter | 7.32e-01 | 8.52e-01 | -4.87e+00 | 1.13e-06 | 6.40e-06 | -1.20e-01 |
| LUSC | cg21033494 | chr10:46045707 | CGI:chr10:46030173-46030750 | promoter,gene body | 7.84e-01 | 8.88e-01 | -2.66e+00 | 7.89e-03 | 1.15e-02 | -1.04e-01 |
| COAD | cg10326726 | chr10:46046316 | CGI:chr10:46030173-46030750 | promoter | 2.87e-01 | 6.46e-01 | -3.92e+00 | 8.94e-05 | 3.21e-04 | -3.59e-01 |
| BLCA | cg10326726 | chr10:46046316 | CGI:chr10:46030173-46030750 | promoter | 2.76e-01 | 4.69e-01 | -2.27e+00 | 2.34e-02 | 2.77e-02 | -1.93e-01 |
| BLCA | cg21033494 | chr10:46045707 | CGI:chr10:46030173-46030750 | promoter,gene body | 7.27e-01 | 8.84e-01 | -3.38e+00 | 7.23e-04 | 1.77e-03 | -1.56e-01 |
| LIHC | cg27607126 | chr10:46046926 | CGI:chr10:46030173-46030750 | promoter | 7.66e-01 | 8.67e-01 | -5.70e+00 | 1.23e-08 | 9.39e-08 | -1.00e-01 |
| LIHC | cg21033494 | chr10:46045707 | CGI:chr10:46030173-46030750 | promoter,gene body | 7.98e-01 | 9.06e-01 | -4.04e+00 | 5.29e-05 | 1.18e-04 | -1.07e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg27607126 | chr10:46046926 | CGI:chr10:46030173-46030750 | promoter | 7.22e-01 | 8.48e-01 | -9.04e+00 | 1.53e-19 | 7.98e-19 | -1.26e-01 |
| HNSC | cg10326726 | chr10:46046316 | CGI:chr10:46030173-46030750 | promoter | 7.88e-01 | 9.27e-01 | -2.09e+00 | 3.64e-02 | 4.02e-02 | -1.39e-01 |
| COAD | cg27607126 | chr10:46046926 | CGI:chr10:46030173-46030750 | promoter | 7.21e-01 | 8.36e-01 | -2.26e+00 | 2.40e-02 | 2.97e-02 | -1.15e-01 |
| BLCA | cg12083644 | chr10:46046165 | CGI:chr10:46030173-46030750 | promoter,gene body | 7.36e-01 | 8.86e-01 | -2.22e+00 | 2.61e-02 | 3.23e-02 | -1.50e-01 |
Top |
Exon skipping events with PSI in TCGA for MSMB |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for MSMB |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for MSMB |
| TFs related to MSMB. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| BRCA | ASCL1 | MSMB | 3.19e+00 | 8.12e-03 | 4.46e+00 | 9.81e-01 | Female-biased |
| BRCA | PATZ1 | MSMB | 3.12e+00 | 2.82e-03 | 4.73e+00 | 9.91e-01 | Female-biased |
| BRCA | TCF12 | MSMB | 3.14e+00 | 6.22e-03 | 4.49e+00 | 9.84e-01 | Female-biased |
| BRCA | TCF3 | MSMB | 3.25e+00 | 3.49e-03 | 4.81e+00 | 9.91e-01 | Female-biased |
| BRCA | ZIC5 | MSMB | 3.77e+00 | 1.35e-02 | 4.89e+00 | 9.81e-01 | Female-biased |
| BRCA | ZNF300 | MSMB | 3.10e+00 | 5.27e-03 | 4.52e+00 | 9.85e-01 | Female-biased |
| BRCA | ZNF331 | MSMB | 3.20e+00 | 2.77e-03 | 4.82e+00 | 9.92e-01 | Female-biased |
| BRCA | ZNF793 | MSMB | 3.55e+00 | 9.34e-03 | 4.79e+00 | 9.85e-01 | Female-biased |
| BRCA | ZNF860 | MSMB | 3.09e+00 | 3.84e-03 | 4.61e+00 | 9.88e-01 | Female-biased |
| CHOL | ZNF331 | MSMB | 2.64e+00 | 2.85e-03 | 3.87e+00 | 9.82e-01 | Female-biased |
| ESCA | ZNF660 | MSMB | 4.24e+00 | 9.80e-01 | 3.54e+00 | 1.13e-02 | Male-biased |
| PAAD | PDX1 | MSMB | 4.62e+00 | 1.34e-02 | 5.37e+00 | 9.85e-01 | Female-biased |
| PAAD | SOX6 | MSMB | 4.06e+00 | 1.09e-02 | 4.85e+00 | 9.86e-01 | Female-biased |
| MSMB related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for MSMB |
| RBPs related to ES in MSMB. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| MSMB related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs75374708 | chr10:53007965:C:A | - | 0.0996399161059071 | 0.0185808766509967 | HNSC | Female-baised eQTL |
| rs145418530 | chr10:37049130:G:A | - | 0.126903269036111 | 0.0351194855765342 | HNSC | Female-baised eQTL |
| rs11003368 | chr10:53077420:T:C | - | 0.123224257254106 | 0.00351578502554924 | LIHC | Female-baised eQTL |
| rs12767906 | chr10:53077558:A:G | - | 0.123224257254106 | 0.00351578502554924 | LIHC | Female-baised eQTL |
| rs11003370 | chr10:53078122:T:A | - | 0.123224257254106 | 0.00351578502554924 | LIHC | Female-baised eQTL |
| rs80054115 | chr10:51958030:T:A | - | 0.109696466783559 | 0.014277537869308 | LIHC | Female-baised eQTL |
| rs10508951 | chr10:51967704:G:T | - | 0.109750604592393 | 0.0143230211721294 | LIHC | Female-baised eQTL |
| rs80117039 | chr10:51959035:C:T | - | 0.109665867394293 | 0.0144990720984473 | LIHC | Female-baised eQTL |
| rs75884457 | chr10:51965887:C:T | - | 0.109683651070292 | 0.0147772274381998 | LIHC | Female-baised eQTL |
| rs74586695 | chr10:51965913:G:A | - | 0.104126793313995 | 0.0245090510306641 | LIHC | Female-baised eQTL |
| rs74132820 | chr10:51933857:A:C | - | 0.103096735584809 | 0.0288008639121931 | LIHC | Female-baised eQTL |
| rs114500910 | chr10:51957453:G:A | - | 0.0990831783163736 | 0.0363916383286719 | LIHC | Female-baised eQTL |
| rs79764379 | chr10:36248786:C:T | - | 0.101043137851361 | 0.037876962999722 | LIHC | Female-baised eQTL |
| rs79343325 | chr10:51962574:C:T | - | 0.0990502221094211 | 0.0381277412251312 | LIHC | Female-baised eQTL |
| rs11003369 | chr10:53077818:C:T | - | 0.0935257492817271 | 0.0491853816533538 | LIHC | Female-baised eQTL |
| rs80296314 | chr10:51975590:G:C | - | 0.111957293107644 | 0.0130112975851681 | LUSC | Female-baised eQTL |
| rs1904044 | chr10:51980502:G:A | - | 0.111957293107644 | 0.0130112975851681 | LUSC | Female-baised eQTL |
| rs60914779 | chr10:44135745:C:A | - | 0.137243727217984 | 0.0135801302872988 | LUSC | Female-baised eQTL |
| rs4565852 | chr10:50947713:T:C | - | 0.117906571633514 | 0.018474398707287 | LUSC | Female-baised eQTL |
| rs16905780 | chr10:54217158:T:A | - | 0.128370331020122 | 0.0203922645424801 | LUSC | Female-baised eQTL |
| rs142317614 | chr10:54219566:T:C | - | 0.128370331020122 | 0.0203922645424801 | LUSC | Female-baised eQTL |
| rs4275567 | chr10:51998529:A:C | - | 0.101641136261615 | 0.0222051572130042 | LUSC | Female-baised eQTL |
| rs79380677 | chr10:37080070:G:T | - | 0.188686487034599 | 0.00411395204034392 | STAD | Female-baised eQTL |
| rs7894252 | chr10:37087060:T:C | - | 0.177627154581791 | 0.00806166534373397 | STAD | Female-baised eQTL |
| rs78131676 | chr10:37091193:A:G | - | 0.177627154581791 | 0.00806166534373397 | STAD | Female-baised eQTL |
| rs143153175 | chr10:37099073:A:T | - | 0.177627154581791 | 0.00806166534373397 | STAD | Female-baised eQTL |
| rs149171158 | chr10:37099856:T:C | - | 0.177627154581791 | 0.00806166534373397 | STAD | Female-baised eQTL |
| rs7918642 | chr10:43843209:A:G | - | 0.146836909110591 | 0.0332211327267447 | STAD | Female-baised eQTL |
| rs912801 | chr10:43963906:C:T | - | 0.216761492914182 | 4.66770984506995e-05 | BLCA | Female-baised eQTL |
| rs58297052 | chr10:43969908:G:A | - | 0.216761492914182 | 4.66770984506995e-05 | BLCA | Female-baised eQTL |
| rs1408941 | chr10:43956392:G:T | - | 0.216464122164886 | 5.0458348730769e-05 | BLCA | Female-baised eQTL |
| rs78621342 | chr10:43960213:C:A | - | 0.216464122164886 | 5.0458348730769e-05 | BLCA | Female-baised eQTL |
| rs12570158 | chr10:43972072:C:T | - | 0.197165365290378 | 0.00028208694310361 | BLCA | Female-baised eQTL |
| rs4948796 | chr10:43967129:C:T | - | 0.181480971237104 | 0.00101146298716263 | BLCA | Female-baised eQTL |
| rs11000634 | chr10:52058737:G:A | - | 0.23669900310633 | 0.00679150383915453 | BLCA | Female-baised eQTL |
| rs10900239 | chr10:42495395:C:G | - | 0.215818287683022 | 0.0356882586412673 | BLCA | Female-baised eQTL |
| rs2016678 | chr10:42558912:C:T | - | 0.215818287683022 | 0.0356882586412673 | BLCA | Female-baised eQTL |
| rs10900248 | chr10:42564224:T:C | - | 0.215818287683022 | 0.0356882586412673 | BLCA | Female-baised eQTL |
| rs12219326 | chr10:42565149:G:A | - | 0.215818287683022 | 0.0356882586412673 | BLCA | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs755120 | chr10:47091849:A:G | - | 0.164409659536779 | 0.011402309307163 | PAAD | Male-baised eQTL |
| rs786822 | chr10:47093223:A:G | - | 0.164409659536779 | 0.011402309307163 | PAAD | Male-baised eQTL |
| rs72792211 | chr10:47094148:C:A | - | 0.164409659536779 | 0.011402309307163 | PAAD | Male-baised eQTL |
| rs709624 | chr10:47080725:T:C | - | 0.15101920953183 | 0.0275377139130219 | PAAD | Male-baised eQTL |
| rs786787 | chr10:47082777:G:C | - | 0.15101920953183 | 0.0275377139130219 | PAAD | Male-baised eQTL |
| rs813092 | chr10:47086246:A:T | - | 0.15101920953183 | 0.0275377139130219 | PAAD | Male-baised eQTL |
| rs34350875 | chr10:55891235:T:G | - | 0.0452591297336076 | 0.0373060873346239 | LIHC | Male-baised eQTL |
| rs12773955 | chr10:55913284:T:G | - | 0.0424737980350542 | 0.0430080426911431 | LIHC | Male-baised eQTL |
| rs11005109 | chr10:55913532:G:A | - | 0.0424737980350542 | 0.0430080426911431 | LIHC | Male-baised eQTL |
| rs11005110 | chr10:55915821:A:G | - | 0.0424737980350542 | 0.0430080426911431 | LIHC | Male-baised eQTL |
| rs11005112 | chr10:55917967:T:C | - | 0.0424737980350542 | 0.0430080426911431 | LIHC | Male-baised eQTL |
| rs11005113 | chr10:55921377:T:C | - | 0.0424737980350542 | 0.0430080426911431 | LIHC | Male-baised eQTL |
| rs12098453 | chr10:55922115:C:A | - | 0.0424737980350542 | 0.0430080426911431 | LIHC | Male-baised eQTL |
| rs11005114 | chr10:55922363:G:A | - | 0.0424737980350542 | 0.0430080426911431 | LIHC | Male-baised eQTL |
| rs34517594 | chr10:55923684:A:G | - | 0.0424737980350542 | 0.0430080426911431 | LIHC | Male-baised eQTL |
| rs12777762 | chr10:55924028:C:A | - | 0.0424737980350542 | 0.0430080426911431 | LIHC | Male-baised eQTL |
| rs12782822 | chr10:55924133:C:T | - | 0.0424737980350542 | 0.0430080426911431 | LIHC | Male-baised eQTL |
| rs2066057 | chr10:55925124:A:G | - | 0.0424548515962737 | 0.0436605989842482 | LIHC | Male-baised eQTL |
| rs71492672 | chr10:55917283:G:A | - | 0.0417192667894439 | 0.0487459141539157 | LIHC | Male-baised eQTL |
| rs72785049 | chr10:49104531:G:A | - | 0.0571459736350962 | 0.0151017161919801 | BLCA | Male-baised eQTL |
| rs61848419 | chr10:49111920:T:G | - | 0.0570961326602416 | 0.0152389025170602 | BLCA | Male-baised eQTL |
| rs17011698 | chr10:49048898:G:C | - | 0.0602604000879402 | 0.0178949536490968 | BLCA | Male-baised eQTL |
| rs57328384 | chr10:49051023:G:T | - | 0.0602349119867543 | 0.0180225914331606 | BLCA | Male-baised eQTL |
| rs7097429 | chr10:45397960:C:G | - | 0.0767326183633493 | 0.00148540552857007 | LUAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000263639 |
| CpG Site: cg17030820 | |
| Position to Gene: promoter | |
| Male Effect: -0.157674022788071 | |
| Female Effect: - | |
 | Gene ID: ENSG00000263639 |
| CpG Site: cg12083644 | |
| Position to Gene: gene,promoter | |
| Male Effect: -0.250827966212425 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg17030820 | chr10:46046561 | promoter | -0.157674022788071 | 9.85453639711947e-05 | -0.4732421216602889 | 8.60729459886272e-07 | PAAD |
| cg12083644 | chr10:46046165 | gene,promoter | -0.250827966212425 | 1.59798825524546e-19 | -0.6157730834583751 | 1.1473088231016212e-24 | LUAD |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of MSMB |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000263639 | MSMB | C0033578 | Prostatic Neoplasms | 3 | CTD_human |
| ENSG00000263639 | MSMB | C0376358 | Malignant neoplasm of prostate | 3 | CTD_human |
| ENSG00000263639 | MSMB | C2677821 | Prostate Cancer, Hereditary, 13 | 1 | CTD_human |
